Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma

Cancer Letters

Volumn 273, Issue 2, 2009, Pages 201-209

  Tam, Ka Ho ^a   Yang, Zhen Fan ^a   Lau, Chi Keung ^a   Lam, Chi Tat ^a   Pang, Roberta W C ^a   Poon, Ronnie T P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemoresistance; Chemosensitivity; HCC; mTOR; p53; RAD001

Indexed keywords

CISPLATIN; CYCLIN D1; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; GENES, P53; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 57349106607     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.018     Document Type: Article

References (27)

1. Bosch F.X., Ribes J., Diaz M., and Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
2. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 127 (2004) S268-S276
3. Poon R.T., Fan S.T., Lo C.M., Ng I.O., Liu C.L., Lam C.M., and Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann. Surg. 234 (2001) 63-70
4. Llovet J.M., Sala M., Castells L., et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31 (2000) 54-58
5. Barbare J.C., Bouche O., Bonnetain F., et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J. Clin. Oncol. 23 (2005) 4338-4346
6. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
7. Yang Z.F., Poon R.T., To J., Ho D.W., and Fan S.T. The potential role of hypoxia inducible factor 1α in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res. 64 (2004) 5496-5503
8. Calvisi D.F., Ladu S., Gorden A., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006) 1117-1128
9. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., and Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103 (2005) 307-312
10. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Human Mutat. 19 (2002) 607-614
11. Faivre S., Kroemer G., and Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5 (2006) 671-688
12. Sieghart W., Fuereder T., Schmid K., et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 83 (2007) 425-432
13. Yan H., Frost P., Shi Y., Hoang B., Sharma S., Fisher M., Gera J., and Lichtenstein A. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 66 (2006) 2305-2313
14. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747-759
15. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.C., Mills G.B., and Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10 (2004) 7031-7042
16. Wu L., Birle D.C., and Tannock I.F. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 65 (2005) 2825-2831
17. Wendel H.G., De Stanchina E., Fridman J.S., et al. Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
18. Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., and Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62 (2002) 6141-6145
19. Chi T.Y., Chen G., Ho L.K., and Lai P. Establishment of a doxycycline-regulated cell line with inducible, doubly-stable expression of the wild-type p53 gene from p53-deleted hepatocellular carcinoma cells. Cancer Cell Int. 5 (2005) 27
20. Aft R.L., Lewis J.S., Zhang F., Kim J., and Welch M.J. Enhancing targeted radiotherapy by copper(II)diacetyl-bis(N4-methylthiosemicarbazone) using 2-deoxy-d-glucose. Cancer Res. 63 (2003) 5496-5504
21. Sheikh M.S., Chen Y.Q., Smith M.L., and Fornace Jr. A.J. Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. Oncogene (1997) 1875-1882
22. Ruan S., Okcu M.F., Pong R.C., Andreeff M., Levin V., Hsieh J.T., and Zhang W. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Clin. Cancer Res. (1999) 197-202
23. Mabuchi S., Altomare D.A., Cheung M., Zhang L., Poulikakos P.I., Hensley H.H., Schilder R.J., Ozols R.F., and Testa J.R. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin. Cancer Res. (2007) 4261-4270
24. Wendel H.G., Malina A., Zhao Z., Zender L., Kogan S.C., Cordon-Cardo C., Pelletier J., and Lowe S.W. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. (2006) 7639-7646
25. G. Hudes, M. Carducci, P. Tomczak, et al., A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC), in: Proceedings of ASCO Annual Meeting, 2006, pp. abstr. LBA4, 18S.
26. A. O'Donnell, S. Faivre, I. Judson, et al., A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours, in: Proceedings of ASCO Annual Meeting, 2003, pp. abstr. 803.
27. R.J. Amato, A. Misellati, M. Khan, S. Chiang, A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC), in: Proceedings of ASCO Annual Meeting, 2006.